Seminar: Industrial Adventures with Marc Prikazsky, CEO of Ceva Santé Animale
In 1999, Sanofi sold its animal health and nutrition businesses, and fourteen executives acquired a portion of them to create Ceva Santé Animale through a management buyout (MBO). Eight years later, Ceva’s management and employees became majority shareholders, enabling them to launch a long-term initiative: promoting animal health and beyond, given that 70% of human infections originate from animals. Ceva has become the leading French animal health company and the fifth-largest globally, with a presence in 47 countries, 21 R&D centers, and 32 production sites. It specializes in three key areas: biology (vaccines), pharmaceuticals and biopharmaceuticals (medicines and therapeutic treatments), and equipment designed to ensure the quality of vaccination. It is developing expertise in three areas: biology (vaccines), pharmacy and biopharmacy (medicines and therapeutic treatments), and equipment to ensure the quality of vaccination. Preventive solutions now exist to control zoonotic diseases in domestic animals and even wildlife, but much remains to be done to engage public authorities in this One Health approach.
Free registration – Registration closes on Thursday, June 18, 2026, at 12:00 p.m.